BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, July 8, 2025
See today's BioWorld
Home
» Tenaya sets out rationale for targeting HDAC6 in heart failure
To read the full story,
subscribe
or
sign in
.
Tenaya sets out rationale for targeting HDAC6 in heart failure
July 12, 2022
By
Cormac Sheridan
Several genetic studies in a range of model organisms have pointed to an important role for the B-cell lymphoma 2 (BCL2)-associated athanogene 3 (
BAG3
) gene in the maintenance of cardiac function.
BioWorld
Science
Cardiovascular